| ARID1A mutations in endometriosis-associated ovarian carcinomas KC Wiegand, SP Shah, OM Al-Agha, Y Zhao, K Tse, T Zeng, J Senz, ... New England Journal of Medicine 363 (16), 1532-1543, 2010 | 2001 | 2010 |
| The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery HG Stunnenberg, S Abrignani, D Adams, M de Almeida, L Altucci, V Amin, ... Cell 167 (5), 1145-1149, 2016 | 567 | 2016 |
| Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma KR Taylor, A Mackay, N Truffaux, YS Butterfield, O Morozova, C Philippe, ... Nature genetics 46 (5), 457-461, 2014 | 531 | 2014 |
| Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profiling A Bashashati, G Ha, A Tone, J Ding, LM Prentice, A Roth, J Rosner, ... The Journal of pathology 231 (1), 21-34, 2013 | 521 | 2013 |
| MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance S Yip, J Miao, DP Cahill, AJ Iafrate, K Aldape, CL Nutt, DN Louis Clinical cancer research 15 (14), 4622-4629, 2009 | 492 | 2009 |
| Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers S Yip, YS Butterfield, O Morozova, S Chittaranjan, MD Blough, J An, I Birol, ... The Journal of pathology 226 (1), 7-16, 2012 | 354 | 2012 |
| Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers M Jansen, S Yip, DN Louis The Lancet Neurology 9 (7), 717-726, 2010 | 331 | 2010 |
| Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells H Wakimoto, G Mohapatra, R Kanai, WT Curry, S Yip, M Nitta, AP Patel, ... Neuro-oncology 14 (2), 132-144, 2011 | 277 | 2011 |
| Detection, characterization, and inhibition of FGFR–TACC fusions in IDH wild-type glioma AL Di Stefano, A Fucci, V Frattini, M Labussiere, K Mokhtari, P Zoppoli, ... Clinical cancer research 21 (14), 3307-3317, 2015 | 276 | 2015 |
| Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma M Snuderl, A Batista, ND Kirkpatrick, CR de Almodovar, L Riedemann, ... Cell 152 (5), 1065-1076, 2013 | 266 | 2013 |
| Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors J Torchia, B Golbourn, S Feng, KC Ho, P Sin-Chan, A Vasiljevic, ... Cancer cell 30 (6), 891-908, 2016 | 257 | 2016 |
| Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome P Panwalkar, J Clark, V Ramaswamy, D Hawes, F Yang, C Dunham, ... Acta neuropathologica 134, 705-714, 2017 | 226 | 2017 |
| Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma LK Donovan, A Delaidelli, SK Joseph, K Bielamowicz, K Fousek, ... Nature medicine 26 (5), 720-731, 2020 | 208 | 2020 |
| Rise of the machines: advances in deep learning for cancer diagnosis AB Levine, C Schlosser, J Grewal, R Coope, SJM Jones, S Yip Trends in cancer 5 (3), 157-169, 2019 | 194 | 2019 |
| Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis J Torchia, D Picard, L Lafay-Cousin, CE Hawkins, SK Kim, L Letourneau, ... The lancet oncology 16 (5), 569-582, 2015 | 191 | 2015 |
| Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer EY Zhao, Y Shen, E Pleasance, K Kasaian, S Leelakumari, M Jones, ... Clinical Cancer Research 23 (24), 7521-7530, 2017 | 189 | 2017 |
| ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors AH Alassiri, RH Ali, Y Shen, A Lum, C Strahlendorf, R Deyell, R Rassekh, ... The American journal of surgical pathology 40 (8), 1051-1061, 2016 | 165 | 2016 |
| Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide J Triscott, C Lee, K Hu, A Fotovati, R Berns, M Pambid, M Luk, RE Kast, ... Oncotarget 3 (10), 1112, 2012 | 157 | 2012 |
| NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma MR Jones, LM Williamson, JT Topham, MKC Lee, A Goytain, J Ho, ... Clinical Cancer Research 25 (15), 4674-4681, 2019 | 156 | 2019 |
| MYCN amplification drives an aggressive form of spinal ependymoma DR Ghasemi, M Sill, K Okonechnikov, A Korshunov, S Yip, PW Schutz, ... Acta neuropathologica 138, 1075-1089, 2019 | 155 | 2019 |
Marco MarraBC Cancer Agency; University of British Columbia, Genome Sciences CentreVerified email at bcgsc.ca
